RESUMEN

The objective of the current study was to examine the effect of replacing maize with new or stored wheat on the nutrient intake, digestibility, digesta viscosity, and growth performance of growing broilers from 1-21 days of age. For this purpose, 560 one-day-old male broiler chicks were randomly divided into seven experimental treatments, each with 8 replicates of 10 birds. The control diet was a corn soybean-based diet, while six other experimental treatments replaced the corn of the control diet with either 50% or 100% of new, 1.5 year, and 2.5-year-old wheat. The results showed that the replacement of corn with new wheat at 50% and 100% in the diet of broilers significantly reduced feed intake and body weight gain, and increased FCR (p<0.05) at week 3. Similarly, in the overall period of the starter phase (1-21 days), replacement of corn with new wheat at 50% and 100% in the diet of broilers significantly reduced feed intake, nutrient digestibility, and body weight gain, and increased digesta viscosity and FCR (p<0.05). Based on the findings of the current study, it is concluded that stored wheat successfully replaces corn and new wheat in the diet of broilers. Furthermore, stored wheat has a positive impact on feed intake, performance parameter, digesta viscosity, and nutrient digestibility as compared to new wheat.(AU)

Asunto(s)

Animales , Masculino , Pollos/fisiología , Ingestión de Alimentos/fisiología , Triticum/fisiología

RESUMEN

Background: Access to effective mental health services in low- and- middle income countries (LMICs) is limited, leading to a substantial global treatment gap. Amitriptyline, an anti-depressant, and diazepam, an anxiolytic drug, are classified as essential medications by the World Health Organization (WHO). They are the only psychotropic medications whose availability in health facilities is documented as part of Service Provision Assessment surveys. Our objective was to characterize the availability of these medicines in seven countries. Methods: We pooled nationally representative data from Service Provision Assessment surveys of health facilities conducted in Bangladesh, Democratic Republic of Congo (DRC), Haiti, Malawi, Nepal, Senegal, and Tanzania, from 2012 to 2018. We estimated the distribution and determinants of facility-level amitriptyline and diazepam availability in each country. Results: We analysed data from 7958 health facilities. An estimated 8.2% of facilities had amitriptyline and 46.1% had diazepam on the day of assessment. There was significant heterogeneity in both amitriptyline and diazepam availability across countries and within countries across facility characteristics. Multivariable models indicated that hospitals, faith-based and private-for-profit facilities, facilities with more staff, and facilities with more technological resources were more likely to have each medicine, relative to primary care facilities, public sector facilities, facilities with fewer staff, and facilities with fewer technological resources, respectively. Conclusion: Our results indicate limited availability of amitriptyline in health facilities in these seven LMICs. Diazepam is much more commonly available than amitriptyline. Efforts to narrow the global treatment gap for mental health - and especially to integrate mental health services into primary care in LMICs - will be limited without the availability of essential medicines like amitriptyline. Efforts to expand purchasing, distribution, and capacity-building in the appropriate use of essential mental health medicines in LMICs are warranted.

Asunto(s)

Medicamentos Esenciales , Salud Mental , Amitriptilina , Bangladesh , República Democrática del Congo , Diazepam/uso terapéutico , Haití , Instituciones de Salud , Accesibilidad a los Servicios de Salud , Humanos , Malaui , Nepal , Senegal , Tanzanía

RESUMEN

The therapeutic responses of many solid tumours to chemo- and radio-therapies are far from fully effective but therapies targeting malignancy-related cellular changes show promise for further control. In head and neck squamous cell carcinoma, the epidermal growth factor receptor (EGFR) is commonly overexpressed and investigation of agents that block this receptor indicate a limited response when used alone but an ability to enhance the actions of other drugs. The hierarchical stem cell patterns present in tumours generate cellular heterogeneity and this is further complicated by cancer stem cells (CSC) shifting between epithelial (Epi-CSC) and mesenchymal (EMT-CSC) states. To clarify how such heterogeneity influences responses to EGFR blocking, we examined the effects of Cetuximab and Erlotinib on the cell sub-populations in HNSCC cell lines. These agents reduced cell proliferation for all subpopulations but induced little cell death. They did however induce large shifts of cells between the EMT-CSC, Epi-CSC and differentiating cell compartments. Loss of EMT-CSCs reduced cell motility and is expected to reduce invasion and metastasis. EGFR blocking also induced shifts of Epi-CSCs into the differentiating cell compartment which typically has greater sensitivity to chemo/radiation, an effect expected to enhance the overall response of tumour cell populations to adjunctive therapies.